This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation
Cost-effectiveness analysis, cost-utility analysis
Study objective
The objective was to assess the cost-effectiveness of ezetimibe in combination with simvastatin for the treatment of patients with primary hypercholesterolaemia.
Interventions
Two treatment scenarios were investigated, one based on Dutch Guidelines and the other on the EASEGO study. The Dutch Guidelines were that patients not achieving their goal of a low-density lipoprotein (LDL) cholesterol level of less than 2.5 millimoles per litre (mmol/L) while on simvastatin 40mg were given either ezetimibe 10mg plus simvastatin 40mg, or atorvastatin 40mg. The EASEGO scenario was that patients not achieving their goal of LDL cholesterol level of less than 2.5mmol/L, while on simvastatin 20mg or atorvastatin 10mg were given either ezetimibe 10mg plus simvastatin 20mg, or atorvastatin 20mg or simvastatin 40mg.
Location/setting
Netherlands/primary care.
Methods

Analytical approach:
A published state-transition Markov model (Cook, et al. 2004 , see 'Other Publications of Related Interest' below for bibliographic details) was used to combine the clinical and economic evidence from published literature to evaluate the cost-effectiveness of the treatment options. A lifetime horizon was adopted. The authors stated that the perspective was societal.
Effectiveness data:
The clinical data came from published clinical and epidemiological studies, relevant to the Dutch setting, including the Dutch EASEGO study, the Dutch Guideline on Cardiovascular Risk Management 2006, and the Dutch Healthcare Performance Report 2008. The key clinical parameters were the change in LDL cholesterol level and the risk of cardiovascular disease events.
Monetary benefit and utility valuations:
The utility estimates were from published age-specific Dutch values for the European Quality of life (EQ-5D) questionnaire.
Measure of benefit:
